After you’re diagnosed with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer, your doctor’s goal is to build a treatment plan that gives you the best chance of controlling your ...
Enhertu showed better outcomes in HR-positive, HER2-negative breast cancer, while Trodelvy was more effective in HR-negative, HER2-null tumors when used first. Real-world data from over 4,000 patients ...
Biomarkers are measurable indicators that can be tested to reveal important details about a cancer. Information about these biomarkers can help guide the best treatment for you, predict your response ...
The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results